Melanotan I

FDA Approved

Melanotan I (Afamelanotide)

Aliases
Afamelanotide, Scenesse
Administration
Subcutaneous implant (FDA-approved route)

Research and regulatory

Development stage

FDA approved (Scenesse, 2019) for erythropoietic protoporphyria, a rare photosensitivity disorder.

Legal and regulatory

FDA approved — Scenesse (afamelanotide) implant, for erythropoietic protoporphyria. Cosmetic tanning use is off-label and unregulated when self-administered.

Side effects

Nausea, implant site reactions, headache, skin darkening